Want to continue viewing company data?

Sign up for exclusive competitive intelligence.
Company Data Subscription $83 per month (billed Annually)
Signup to View Free Sample

Cerus Corp (Cerus) is a biomedical products company that focuses on the field of blood transfusion safety. It develops and commercializes Intercept blood system, which reduces the risk of transfusion-transmitted infections by inactivating a wide range of pathogens including viruses, bacteria, and parasites present in donated blood. The Intercept blood system is for use with blood components including platelets, plasma, and red blood cells. It is also used to produce PRCFC, and pathogen reduced plasma and cryoprecipitate. The company markets and sells the Intercept blood system through its direct sales force and distributors in several countries including the US, Europe, the Commonwealth of Independent States (CIS), Latin America, the Middle East, and selected countries in other regions. Cerus is headquartered in Concord, California, the US.

Headquarters United States of America

Address 2550 Stanwell Drive, Concord, California, 94520


Telephone 1 925 2886000

No of Employees 294

Industry Medical Equipment

Ticker Symbol & Exchange CERS (NASD)

Revenue (2021) $159.5M 39.6% (2021 vs 2020)

EPS XXX

Net Income (2021) XXX 9.2% (2021 vs 2020)

Market Cap* $914.6M

Net Profit Margin (2021) XXX 34.9% (2021 vs 2020)

* As of and is in US$

Explore premium data & analytics

20+

Medical Clinical Trials

A database of clinical trials planned, currently ongoing, completed, suspended, withdrawn, and terminated in countries around the world.

19+

Clinical Trials

Determine Cerus Corp go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

5

Pipeline Drugs

Identify which of Cerus Corp’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

5

Medical Pipeline Products

A database of medical devices that are in the process to get approved for sale around the world. Devices that are in development, through to those in the approval process are included.

4

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Cerus Corp’s relevant decision makers and contact details.

2

Medical Marketed Products

A database of medical devices currently for sale around the world. Devices that have been approved by a regulatory authority are included.

1

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

Subscribe to Company Analytics & gain access to premium industry data & analytics Subscribe to Company Analytics & gain access to premium industry data & analytics Start Here

Products and Services

Products Brands
UVA Illumination Devices Intercept
Intercept Blood System for Platelets and Plasma
Intercept Disposable Kits
XXX
XXX
XXX
Subscribe to Company Analytics for access to more products & services data Subscribe to Company Analytics for access to more products & services data Learn More

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2022 Contracts/Agreements In May, the company entered into an agreement with Fresenius Kabi for the production of INTERCEPT Blood System sets.
2022 Contracts/Agreements In April, the company signed a five-year contract with the American Red Cross for the INTERCEPT blood system for platelets.
2021 Contracts/Agreements In June, the company entered into an agreement with LifeSouth Community Blood Centers for being a production partner for INTERCEPT Fibrinogen Complex.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Get Started
Image for loader

Competitor Comparison

Key Parameters Cerus Corp Grifols SA Octapharma AG Kedrion Biopharma Inc MacoPharma International Gmbh
Headquarters United States of America Spain Switzerland United States of America Germany
City Concord Barcelona Lachen Fort Lee Langen
State/Province California - Schwyz New Jersey Hessen
No. of Employees 294 23,233 9,977 - -
Entity Type Public Public Private Private Private
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more

Key Financial Charts

Operating Margin
Operating Margin
EPS (Earnings per Share)
EPS (Earnings per Share)
Debt to Equity Ratio
Debt to Equity Ratio
Return on Assets
Return on Assets
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Daniel N. Swisher Jr. Chairman Executive Board 2013 59
William M. Greenman President; Director; Chief Executive Officer Executive Board 2011 55
Kevin D. Green Chief Financial Officer; Vice President - Finance Senior Management 2013 50
Vivek K. Jayaraman Chief Operating Officer Senior Management 2020 47
Chrystal N. Menard Chief Legal Officer; General Counsel Senior Management 2012 51
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Gain more insight into company management & employee structure with Company Analytics Gain more insight into company management & employee structure with Company Analytics Subscribe
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer